

Contents

Preface *XV*

List of Contributors *XVII*

1 Post-Translational Modifications in the Context of Therapeutic Proteins: An Introductory Overview *1*

Gary Walsh

- 1.1 Introduction *1*
- 1.2 Biopharmaceuticals and the Biopharmaceutical Sector *1*
- 1.3 Protein Post-Translational Modification *2*
- 1.4 PTMs in the Context of Biopharmaceuticals *7*
- 1.5 Some Specific PTMs *8*
- 1.5.1 Glycosylation *8*
- 1.5.2 Disulfide Bond Formation and Proteolytic Cleavage *10*
- 1.5.3 γ -Carboxylation and β -Hydroxylation *11*
- 1.5.4 Amidation and Sulfation *12*
- 1.6 Extending and Engineering PTM Profiles *12*
- 1.7 Conclusion *13*
- References *14*

Part One Glycosylation *15*

2 Protein Glycosylation: The Basic Science *17*

Susan A. Brooks

- 2.1 Introduction – Glycosylated Proteins *17*
- 2.2 Basic Building Blocks of Glycosylation in Human Cells *18*
- 2.3 Formation of Complex Glycan Structures *19*
- 2.3.1 α and β Glycosidic Bonds *19*
- 2.3.2 Structural Complexity of Glycoprotein Glycans *19*
- 2.4 Glycan Synthesis is Catalyzed by Enzymes of Glycosylation – the “Glycozymes” *22*

2.5	Protein Glycosylation – Relationship Between N-linked and O-linked Glycoproteins	23
2.6	N-linked Glycoproteins	24
2.6.1	Where Does N-linked Glycosylation of Proteins Take Place?	24
2.6.2	Why is it Called N-linked?	24
2.6.3	N-Glycosylation Step-by-Step	24
2.6.3.1	Polypeptide Enters the RER	24
2.6.3.2	Building and Positioning the Dolichol Oligosaccharide Precursor	24
2.6.3.3	Attachment of the Dolichol Oligosaccharide Precursor to the Polypeptide Chain	25
2.6.3.4	Trimming the Dolichol Oligosaccharide Precursor in the RER	25
2.6.3.5	Processing of N-linked Oligosaccharides in the Golgi Apparatus	25
2.6.4	Three Classes of N-linked Glycoproteins	25
2.6.5	What Determines Whether a Potential Site of N-Glycosylation on the Polypeptide Chain is Occupied or Not?	27
2.7	O-linked Glycoproteins	27
2.7.1	Why is it Called O-linked?	28
2.7.2	Different Types of O-linked Glycosylation	28
2.7.3	Overview of O-linked Mucin-Type Protein Glycosylation	28
2.7.4	No Consensus Sequence for Mucin-Type O-linked Glycoprotein Glycosylation	29
2.7.5	Synthesis of O-linked Mucin-Type Glycan Core Structures Step-by-Step	29
2.7.5.1	Initiation – Synthesis of GalNAc α 1 \rightarrow Ser/Thr (Tn Epitope)	29
2.7.5.2	Synthesis of NeuNAc(α 2 \rightarrow 6)GalNAc α 1 \rightarrow Ser/Thr (Sialyl Tn)	29
2.7.5.3	Synthesis of Core 1, Gal(β 1 \rightarrow 3)GalNAc α -Ser/Thr, or the Thomsen–Friedenreich (T or TF) Antigen	29
2.7.5.4	Synthesis of Core 2, GlcNAc(β 1 \rightarrow 6)[Gal(β 1 \rightarrow 3)]GalNAc α 1-Ser/Thr	31
2.7.5.5	Synthesis of Core 3, GlcNAc(β 1 \rightarrow 3)GalNAc α 1 \rightarrow Ser/Thr	31
2.7.5.6	Synthesis of Core 4, GlcNAc(β 1 \rightarrow 6)[GlcNAc(β 1 \rightarrow 3)]GalNAc α 1-Ser/Thr	31
2.7.5.7	Less Common Core Structures	31
2.7.6	Regulation of O-Glycan Synthesis	32
2.8	O- and N-linked Glycan Chain Extension and Commonly Occurring Glycan Motifs	32
2.8.1	Type I Chains or Neolactosamine Units, Gal(β 1 \rightarrow 3)GlcNAc/GalNAc	32
2.8.2	Type 2 Chains or Lactosamine Units, Gal(β 1 \rightarrow 4)GlcNAc	33
2.8.3	Termination of Glycan Chains	33
2.8.4	Blood Group Antigens	33
2.9	Analytical Methodologies Developed to Detect and Characterize Glycosylation	33
2.9.1	Glycan Analysis is Complex and Requires a Number of Techniques	33

2.9.2	Detection of Glycans	34
2.9.2.1	Periodic Acid-Schiff (PAS) Reaction	34
2.9.2.2	Recognition Through Lectin Binding	34
2.9.2.3	Pulsed Amperometric Detection (PAD) of Unlabelled Free Glycans	35
2.9.2.4	Labeling Glycans with Radiolabels or Fluorescent Labels	35
2.9.3	Profiling Glycans Using Microarrays	35
2.9.4	One- and Two-Dimensional Gel Electrophoresis – Exploring the Glycome	36
2.9.5	Chemical Release and Analysis of Monosaccharides	36
2.9.6	Chemical Release of Intact Oligosaccharides	37
2.9.7	Enzymatic Release of Intact Oligosaccharides	37
2.9.8	Sequential Exoglycosidase Digestions to Provide Monosaccharide Sequence and Linkage Data	37
2.9.9	Oligosaccharide Separation and Mapping by High-Performance Liquid Chromatography (HPLC)	38
2.9.9.1	Normal Phase HPLC (NP-HPLC)	38
2.9.9.2	Weak Anion Exchange High-Performance Liquid Chromatography (WAX-HPLC)	38
2.9.9.3	High-Performance (or High pH) Anion Exchange Chromatography (HPAEC)	39
2.9.10	Separation and Mapping of Oligosaccharides by Fluorophore-Assisted Carbohydrate Electrophoresis (FACE)	39
2.9.11	Separation and Mapping of Oligosaccharides by Capillary Electrophoresis (CE)	39
2.9.12	Oligosaccharide Analysis by Nuclear Magnetic Resonance (NMR)	40
2.9.13	Determining the Mass of an Oligosaccharide Using Mass Spectrometry (MS)	40
2.9.14	Gas–Liquid Chromatography (GLC)/MS for Determining the Linkage Position of Monosaccharides in Oligosaccharides	41
2.10	Conclusion	42
	References	42
3	Mammalian Cell Lines and Glycosylation: A Case Study	51
	<i>Michael Butler</i>	
3.1	Introduction	51
3.2	The Choice of Cell Line for Glycoprotein Production	51
3.3	Effect of Growth and Protein Production Rate on Glycosylation	54
3.4	Enzymes Associated with Glycan Heterogeneity	55
3.4.1	N-Acetyl Glucosaminyltransferases	55
3.4.2	Fucosylation	57
3.4.3	Sialylation	58
3.5	Immunogenicity of Non-Human Glycans	61
3.6	Culture Parameters that may Affect Glycosylation	61
3.6.1	Nutrient Depletion	61

3.6.2	Fed-Batch Cultures and Supplements	63
3.6.2.1	Glucosamine as a Supplement	64
3.6.2.2	Galactose as a Supplement	65
3.6.3	Ammonia	65
3.6.4	pH	66
3.6.5	Oxygen	66
3.7	Functional Glycomics	67
3.8	Conclusion	68
	References	69
4	Antibody Glycosylation	79
	<i>Roy Jefferis</i>	
4.1	Introduction	79
4.2	Antibodies	80
4.2.1	Basic Structure/Function	80
4.2.2	Antibody (Immunoglobulin) Isotypes	84
4.3	Glycosylation	84
4.3.1	Glycosylation of Normal Human IgG	84
4.3.2	Impact of Glycosylation on Structure	86
4.3.3	Impact of Glycosylation on Stability	87
4.4	IgG-Fc Effector Functions	88
4.4.1	Inflammatory Cascades	88
4.4.2	Catabolism, Pharmacokinetics and Placental Transport	90
4.5	Individual IgG-Fc Glycoforms	91
4.5.1	Individual IgG-Fc Glycoforms and Effector Activities	91
4.5.2	Sialylation of IgG-Fc Oligosaccharides	92
4.5.3	Influence of Galactosylation on IgG-Fc Activities	92
4.5.4	Influence of Fucose and Bisecting <i>N</i> -Acetylglucosamine on IgG-Fc Activities	94
4.6	IgG-Fab Glycosylation	96
4.7	Recombinant Monoclonal Antibodies for Therapy	98
4.8	Conclusions and Future Perspectives	100
	References	100
5	Gonadotropins and the Importance of Glycosylation	109
	<i>Alfredo Ulloa-Aguirre, James A. Dias, and George R. Bousfield</i>	
5.1	Introduction	109
5.2	Structure of Gonadotropins	111
5.3	Glycosylation of Gonadotropins and Structural Microheterogeneity	114
5.4	Role of Glycosylation in the Function of Gonadotropins	121
5.4.1	Role in Folding, Subunit Assembly and Secretion	121
5.4.2	Metabolic Clearance Rate	122
5.4.3	Binding and Signal Transduction	123
5.4.4	LH and FSH Glycoforms and Gonadotropin Function	124

5.4.5	Chorionic Gonadotropin Glycoforms and Function	126
5.5	Regulation of Gonadotropin Glycosylation	127
5.5.1	Effects of Estrogens	127
5.5.2	Effects of Androgens	128
5.5.3	Effects of Gonadotropin-Releasing Hormone	129
5.6	Therapeutic Applications of Gonadotropins	130
5.7	Conclusions	132
	References	133
6	Yeast Glycosylation and Engineering in the Context of Therapeutic Proteins	149
	<i>Terrance A. Stadheim and Natarajan Sethuraman</i>	
6.1	Introduction	149
6.2	N-Glycosylation in Fungi	150
6.3	O-Glycosylation in Fungi and Mammals	152
6.4	Remodeling Yeast Glycosylation for Therapeutic Protein Production	154
	References	160
7	Insect Cell Glycosylation Patterns in the Context of Biopharmaceuticals	165
	<i>Christoph Geisler and Don Jarvis</i>	
7.1	Introduction	165
7.2	Recombinant N-Glycoproteins in the BEVS Product Pipeline	166
7.2.1	Chimigen [™] Vaccines	167
7.2.2	FluBlok [™]	167
7.2.3	Influenza Virus-Like Particles	167
7.2.4	Provenge [®]	167
7.2.5	Specifid [™]	168
7.3	Insect Glycoprotein N-Glycan Structure	168
7.3.1	Typical N-Glycan Structures	168
7.3.2	Hybrid/Complex N-Glycans	170
7.3.3	Sialylated N-Glycans	170
7.3.4	Summary	170
7.4	N-Glycan Processing Enzymes in the BEVS	171
7.4.1	Processing β -N-Acetylglucosaminidase	171
7.4.2	Core α 1,3 Fucosyltransferase	172
7.4.3	Lack of Mannose-6-Phosphate	172
7.5	Lack of Glycosyltransferases	173
7.5.1	N-Acetylglucosaminyltransferases II–IV	173
7.5.2	N-acetylgalactosaminyl-Galactosyl- and Sialyltransferase	173
7.5.3	Glycosyltransferase Donor Substrates	174
7.6	Use of Baculoviruses to Extend BEVS N-Glycosylation	174
7.6.1	Promoter Choice	174
7.6.2	Baculovirus Encoded Glycosyltransferases	175

7.6.2.1	N-Acetylglucosaminyltransferase I	175
7.6.2.2	Galactosyltransferase	175
7.6.2.3	Sialyltransferase	175
7.6.2.4	N-acetylglucosaminyltransferase II	176
7.6.2.5	Trans-Sialidase	176
7.6.3	Baculoviruses Encoded Sugar Processing Genes	176
7.6.3.1	UDP-GlcNAc 2-Epimerase/ <i>N</i> -Acetylmannosamine Kinase	176
7.6.3.2	Sialic Acid Synthetase	177
7.6.3.3	CMP-Sialic Acid Synthetase	177
7.6.4	Summary	177
7.7	Transgenic Insect Cell Lines	178
7.7.1	Proof of Concept	178
7.7.2	Transgenic Glycosyltransferases	179
7.7.2.1	Galactosyltransferase	179
7.7.2.2	Sialyltransferase	179
7.7.2.3	N-Acetylglucosaminyltransferase II	180
7.7.3	Transgenic Sugar Processing Genes	180
7.7.4	Use of Transposon-Based Systems	181
7.7.5	Summary	181
7.8	Sugar Supplementation	182
7.9	Future Directions	182
7.9.1	Completing the <i>N</i> -Glycosylation Pathway	183
7.9.2	Reducing Deleterious Activities	183
	References	184

8	Getting Bacteria to Glycosylate	193
	<i>Michael Kowarik and Mario F. Feldman</i>	
8.1	Introduction	193
8.1.1	Overview and Background	193
8.1.2	Bacterial Protein Glycosylation	194
8.2	<i>N</i> -Glycosylation	194
8.2.1	Introduction	194
8.2.2	The Acceptor Protein	195
8.2.2.1	Primary Acceptor Consensus	196
8.2.2.2	Conformational Requirements for <i>N</i> -Glycosylation	196
8.2.2.3	Crystal Structures of Bacterial <i>N</i> -Glycoproteins	197
8.2.3	The LLO Substrate and the <i>N</i> -OTase, PglB	197
8.3	<i>O</i> -Glycosylation	199
8.3.1	<i>O</i> -Glycosylation in <i>Pseudomonas aeruginosa</i>	200
8.3.1.1	Introduction	200
8.3.1.2	The Acceptor Protein for <i>O</i> -Glycosylation	200
8.3.1.3	Glycan Structures in <i>P. aeruginosa</i> <i>O</i> -Glycosylation	201
8.3.2	<i>O</i> -Glycosylation in <i>Neisseria</i>	201
8.3.2.1	Introduction	201
8.3.2.2	PglL, the <i>O</i> -OTase of <i>N. meningitidis</i>	201

8.3.2.3	Glycan Substrates for <i>N. meningitidis</i> O-Glycosylation	202
8.4	Exploitation of N- and O-Linked Glycosylation	203
8.4.1	Therapeutic (Human) Proteins	203
8.4.2	Bioconjugate Vaccines	204
8.4.3	Glycoengineering	205
	References	206

Part Two Other Modifications 209

9 Biopharmaceuticals: Post-Translational Modification Carboxylation and Hydroxylation 211

Mark A. Brown and Leisa M. Stenberg

9.1	Introduction	211
9.2	γ -Carboxylation	211
9.2.1	Biological Function of γ -Carboxylation	211
9.2.2	The Gla Domain	214
9.2.3	Biosynthesis of Gla	217
9.2.4	γ -Carboxylated Biopharmaceuticals	219
9.2.4.1	Factor IX	219
9.2.4.2	Factor VIIa	221
9.2.4.3	Protein C/Activated Protein C	222
9.2.4.4	Prothrombin	223
9.2.4.5	Conotoxins	224
9.2.5	Enhancement of Cellular Carboxylation Capacity	224
9.2.5.1	Enhanced Expression of the γ -Carboxylation Machinery	225
9.2.5.2	Inhibition of Calumenin Expression	226
9.2.5.3	Propeptide/Propeptidase Engineering	226
9.2.6	Purification of γ -Carboxylated Proteins	226
9.2.7	Analytical Characterization of γ -Carboxylated Proteins	227
9.2.7.1	Methods for Detecting Gla	227
9.2.7.2	Metal Content	227
9.2.7.3	Metal Binding-Induced Structural Changes	228
9.2.7.4	Phospholipid Membrane Binding Assays	228
9.2.7.5	γ -Carboxylase Enzyme Assays	228
9.3	Post-Translational Hydroxylation	229
9.3.1	Biological Function of Hydroxylation	229
9.3.2	Biosynthesis of Hydroxylated Amino Acids	231
9.3.2.1	Biosynthesis of Hya/Hyn	231
9.3.2.2	Biosynthesis of Hydroxyproline	232
9.3.3	Hydroxylated Biopharmaceuticals	233
9.3.3.1	Factor IX	233
9.3.3.2	Protein C/Activated Protein C	233
9.3.3.3	Conotoxins	234
9.3.4	Analytical Characterization of β -Hydroxylated Proteins	235
9.3.4.1	Methods for Detecting Hya/Hyn	235

9.3.4.2	β -Hydroxylase Enzyme Assays	235
9.4	Conclusions	235
	References	236
10	C-Terminal α-Amidation	253
	<i>Nozer M. Mehta, Sarah E. Carpenter, and Angelo P. Consalvo</i>	
10.1	Introduction	253
10.2	Substrate Specificity of PAM	253
10.3	Activity of PAM	254
10.3.1	Assays for Measurement of PAM Activity	254
10.3.2	Mechanism of Action	255
10.3.3	Species Distribution of α -Amidated Peptides and PAM	257
10.4	Genomic Structure and Processing of PAM	257
10.4.1	Organization of the PAM Gene	257
10.4.2	Tissue-Specific Forms of PAM	258
10.5	Structure–Activity Relationships (SAR) for Rat PAM Activity	258
10.6	α -Amidation of Glycine-Extended Peptides	260
10.6.1	<i>In Vitro</i> α -Amidation	260
10.6.2	Optimization of the PAM Reaction <i>In Vitro</i>	261
10.7	Cloning and Expression of Various Forms of PAM	263
10.7.1	PHM, PHMcc and PAL	264
10.7.2	Bifunctional PAM	264
10.7.3	Co-expression of PAM with Glycine-Extended Peptides	265
10.8	A Process for Recombinant Production of α -Amidated Peptides	265
10.8.1	Expression of Glycine-Extended Peptides in <i>E. coli</i> by a Direct Expression Process	266
10.8.2	Purification of the Glycine-Extended Peptides	266
10.8.3	Expression of PAM in CHO Cells	267
10.8.4	Purification of Recombinant PAM (rPAM)	267
10.8.5	Post-Amidation Purification	268
10.8.6	Expression Levels of Peptides by Direct Expression Technology	269
10.9	Marketed Peptides	269
10.9.1	Marketed α -Amidated Peptides	269
10.10	Conclusions	271
	References	271
11	Disulfide Bond Formation	277
	<i>Hayat El Hajjaji and Jean-François Collet</i>	
11.1	Introduction	277
11.2	Disulfide Bonds have a Stabilizing Effect	278
11.3	Disulfide Bond Formation is a Catalyzed Process	278
11.4	Disulfide Bond Formation in the Bacterial Periplasm	278
11.4.1	The Oxidation Pathway: DsbA and DsbB	279
11.4.1.1	DsbA, a very Oxidizing Protein	279
11.4.1.2	DsbB	280

11.4.1.3	DsbB is Reoxidized by the Electron Transport Chain	280
11.4.1.4	Engineering of a New Oxidation Pathway	281
11.4.2	Disulfide Isomerization Pathway	282
11.4.2.1	DsbC, a Periplasmic Protein Disulfide Isomerase	282
11.4.2.2	DsbC is a Dimeric Protein	284
11.4.2.3	DsbC is Kept Reduced by DsbD	284
11.4.2.4	DsbC can Function Independently of DsbD	285
11.4.2.5	DsbG, a Controversial Protein Disulfide Isomerase	285
11.5	Disulfide Bond Formation in the Cytoplasm	286
11.6	Formation of Protein Disulfide Bond in Heterologous Proteins Expressed in <i>E. coli</i>	288
11.7	Disulfide Bond Formation in the Endoplasmic Reticulum	288
11.7.1	PDI Functions both as an Oxidase and an Isomerase	288
11.7.2	PDI is Reoxidized by Ero1	289
11.7.3	Regulation of Ero1	290
11.8	Conclusions	290
	References	290

Part Three Engineering of PTMS 295

12	Glycoengineering of Erythropoietin	297
	<i>Steve Elliott</i>	
12.1	Introduction	297
12.2	Endogenous Epo, rHuEpo and their Attached Carbohydrates	298
12.2.1	Rules for Attachment of Carbohydrates	300
12.2.2	Carbohydrate Glycoforms and their Effect on Structure and Activity	302
12.2.3	Glycoengineering of New Molecules – Darbepoetin Alfa	303
12.2.4	Glycoengineering of New Molecules – AMG114	307
12.2.5	Glycoengineered ESAs and Biological Activity	308
12.3	Effect of Carbohydrate on Clearance, Mechanism of Clearance	309
	References	311
13	Glycoengineering: Cerezyme as a Case Study	319
	<i>Scott M. Van Patten and Tim Edmunds</i>	
13.1	Introduction	319
13.2	Basis for Glycan-Directed Enzyme Replacement Therapy for LSDs	319
13.2.1	Lysosomal Storage Diseases	319
13.2.2	Gaucher Disease	320
13.2.3	Glucocerebrosidase	321
13.2.4	Enzyme Replacement as a Therapy for LSDs	322
13.3	Use of Placental Glucocerebrosidase for ERT	323
13.3.1	Initial Clinical Studies with Unmodified GCase Isolated from Placenta	323

13.3.2	Identification of Mannose Receptor and its Role in Macrophage Uptake	324
13.3.3	Glycoengineering via Sequential Removal of Glycans	324
13.3.4	Development of First ERT for Gaucher Disease – Ceredase	325
13.4	Development of a Second-Generation ERT using Recombinant Technology	327
13.4.1	Production of a CHO Cell-Expressed Recombinant Human GCase – Cerezyme	327
13.4.2	Biochemical Comparison of Cerezyme to Ceredase	327
13.4.3	Comparison of Ceredase to Cerezyme <i>In Vivo</i>	329
13.5	Alternative Strategies for Glycoengineered GCase	330
13.5.1	Overview of Possible Strategies for Targeting Mannose Receptor	330
13.5.2	Use of Mannosidase Inhibitors	330
13.5.3	Use of Mutant Cell Lines	333
13.5.4	Use of Alternative Expression Systems	333
13.6	Summary	334
	References	334
14	Engineering in a PTM: PEGylation	341
	<i>Gian Maria Bonora and Francesco Maria Veronese</i>	
14.1	Protein PEGylation	341
14.2	General Properties of PEG	343
14.3	Chemically Activated PEGs and the Process of PEGylation	344
14.4	Potential Effects of PEGylation that are of Therapeutic Relevance	347
14.5	Some Specific PEGylated Biopharmaceuticals	349
14.6	Conclusions	352
	References	353
	Index	359